# BPC-157 References: The Cited Studies and FDA Sources

> BPC-157 references: the full citation list behind this digest — peer-reviewed tendon, muscle, mechanism, pharmacokinetic, and human-pilot studies, plus the FDA 503A compounding sources, with DOIs, PMIDs, and URLs.

Every BPC-157 study and FDA source cited across this site, listed with DOI, PMID, and URL — the preclinical base, the pharmacokinetics, the human pilots, and the regulatory record.

## How to read this list

Every quantitative claim on this site maps to a numbered entry below. The BPC-157 references run from the foundational cytoprotection and tendon work of the early 2000s through the 2017 angiogenesis mechanism study, the 2022 pharmacokinetic characterization, and the 2024-2026 human pilots and reviews. The regulatory sources are FDA pages, each verified loading and containing the cited BPC-157 entry. Peer-reviewed entries carry a PMID and, where available, a DOI; FDA entries carry the agency URL.

The weight of this list tells the same story the rest of the site does: a deep, citation-dense preclinical base, and a small set of human pilots and reviews at the top.

## References

[1] Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[3] Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[4] Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. https://pubmed.ncbi.nlm.nih.gov/15052688/
[5] Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. https://pubmed.ncbi.nlm.nih.gov/18668315/
[6] Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81-88. https://pubmed.ncbi.nlm.nih.gov/20190676/
[7] Sikiric P, Gojkovic S, Knezevic M, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3221. https://pubmed.ncbi.nlm.nih.gov/36551977/
[8] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
[9] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[10] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[11] Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. https://pubmed.ncbi.nlm.nih.gov/39325560/
[12] Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Acute Pancreatitis. Medicina (Kaunas). 2025;61(2):291. https://pubmed.ncbi.nlm.nih.gov/40005408/
[13] BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1450. https://pubmed.ncbi.nlm.nih.gov/41155565/
[14] Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. https://pubmed.ncbi.nlm.nih.gov/41599743/
[15] Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. https://pubmed.ncbi.nlm.nih.gov/38675421/
[16] U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (BPC-157 free base / BPC-157 acetate, Category 2; effective 2023-09-29) and Bulk drug substances used in compounding under section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[17] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; January 7, 2025 revised interim policy under which newly nominated substances are no longer placed in numbered categories). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[18] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, and MOTs-C listed as substances being considered for inclusion on the 503A Bulks List). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

---

A registered readout of the published BPC-157 record — each finding logged to its layer, the present-tense 503A status printed first, with no pharmacy behind the console and nothing here dispensed or for sale.